Condition: Non-small Cell Lung Cancer · EGFR Exon 20 Insertion Mutation · Sponsor: Groupe Francais De Pneumo-Cancerologie
The goal of this prospective, interventional study is to evaluate the mechanisms of acquired resistance to amivantamab monotherapy in patients with advanced NSCLC with EGFR ins20. The main question it aims to answer is: What are the mechanisms of acquired resistance to amivantamab monotherapy in this population of patients ? How anticipate the efficacy of subsequent systemic therapies ? After this information session, the participant will be asked to sign the study informed consent. A blood samples (2\*10 mL on ethylenediaminetetraacetic acid (EDTA)) will be taken at time of disease progression and will be sent for central liquid biopsy ctDNA analysis. If available, tumor tissue will also be sent for DNA NGS analysis.
This description comes directly from the study's public registry record.
Laurent GRELLIER · +33 (0)4 91 96 59 01 · laurent.greillier@ap-hm.fr
Soizic Ferlandin · soizic_ferlandin@yahoo.fr
Always discuss trial participation with your own doctor first.
| Oncologie Polyclinique Bordeaux Nord Aquitaine | Bordeaux, France | Not Yet Recruiting |
| Centre Hospitalier du Morvan | Brest, France | Recruiting |
| Pneumologie Centre Hospitalier Intercommunal de Créteil | Créteil, France | Recruiting |
| Oncologie, CLCC Dijon | Dijon, France | Not Yet Recruiting |
| Pneumologie, CHU Grenoble | Grenoble, France | Recruiting |
| Pneumologie CH | Le Mans, France | Not Yet Recruiting |
| Oncologie thoracique Hôpital Nord | Marseille, France | Recruiting |
| Oncologie, Centre Antoine Lacassagne | Nice, France | Withdrawn |
| Oncologie Institut Curie | Paris, France | Not Yet Recruiting |
| Hôpital Cochin | Paris, France | Recruiting |
| Pneumologie, Hôpital Tenon | Paris, France | Recruiting |
| Pneumologie Centre Hospitalier | Pau, France | Not Yet Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06247826